Sun Pharmaceutical Industries Limited reported earnings results for the second quarter and six months ended September 30, 2024. For the second quarter, the company reported sales was INR 132,642.2 million compared to INR 120,031.1 million a year ago. Revenue was INR 136,453.9 million compared to INR 124,860.2 million a year ago. Net income was INR 30,401.6 million compared to INR 23,755.1 million a year ago. Basic earnings per share from continuing operations was INR 12.7 compared to INR 9.9 a year ago. Diluted earnings per share from continuing operations was INR 12.7 compared to INR 9.9 a year ago.
For the six months, sales was INR 257,887.3 million compared to INR 237,882.6 million a year ago. Revenue was INR 268,306.9 million compared to INR 246,313 million a year ago. Net income was INR 58,757.8 million compared to INR 43,980.5 million a year ago. Basic earnings per share from continuing operations was INR 24.5 compared to INR 18.3 a year ago. Diluted earnings per share from continuing operations was INR 24.5 compared to INR 18.3 a year ago.
Sun Pharmaceutical Industries Ltd. is one of the Indian leaders of pharmaceutical groups. Net sales break down by family of products as follows:
- generic and OTC medicines (94%): for cardiologic, psychiatric, neurological, gastroenterological, diabetic and respiratory diseases treatment;
- other (6%) : primarily active pharmaceutical ingredients.
At the end of March 2021, the group had 44 production plants worldwide.
Net sales are distributed geographically as follows: India (33%), the United States (31.3%), other (35.7%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
